Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ESRRB | O95718 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17361242 | 0.89 | ALDH1A1 (0.51) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL17385252 | 0.88 | ALDH1A1 (0.50) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| Bromide SCHEMBL28529432 | 0.88 | ALDH1A1 (0.50) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL15132436 | 0.86 | LMNA (0.49) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL13285868 | 0.86 | LMNA (0.49) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL27065040 | 0.86 | LMNA (0.49) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| Bromide SCHEMBL5074991 | 0.85 | LMNA (0.48) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| Bromide SCHEMBL5075234 | 0.85 | LMNA (0.48) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL17777240 | 0.83 | ALDH1A1 (0.36) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL1629392 | 0.82 | ALDH1A1 (0.44) | ALDH1A1LMNAKDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964596-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090227635-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-0550697-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING FUNCTIONALIZED VINYLAZOLES, USE OF THESE VINYLAZOLES FOR PRODUCING MEDICAMENTS, THESE VINYLAZOLES THEMSELVES AND PROCESS FOR PRODUCING THE SAME | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992010482-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING FUNCTIONALIZED VINYLAZOLES, USE OF THESE VINYLAZOLES FOR PRODUCING MEDICAMENTS, THESE VINYLAZOLES THEMSELVES AND PROCESS FOR PRODUCING THE SAME | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227635-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, ABCB11, ACER2 | ALDH1A1 417/4885LMNA 1598/4885KDM4E 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.